22APR

LSIMF sends £80m+ to four regional sites

3 min read

17:16UTC

Barnstaple, Birmingham, Haverhill, Hengoed. Every Life Sciences Innovative Manufacturing Fund cheque this round landed outside the Golden Triangle, and the geography is the whole point.

← Back to Britain's innovation pipe leaks at both ends Jump to analysis ↓

TechnologyDeveloping

Key takeaway

LSIMF's regional spread turns life sciences capex into a deliberate tool of industrial geography rather than a research grant.

The Life Sciences Innovative Manufacturing Fund (LSIMF) allocated over £80m to four UK sites on 14 April 2026: Accord Healthcare in Barnstaple received over £45m for generic and bipolar-medicine manufacturing; the University of Birmingham's Precision Health Technologies Accelerator received £10m for cell and gene therapy and mRNA biomanufacturing; Codis in Haverhill received funding for a spray-drying facility for cancer and neurodegenerative therapies, creating 29 new jobs; and Norgine in Hengoed, South Wales, received over £20m for pharmaceutical facility expansion. ¹

LSIMF sits inside the UK's broader life sciences industrial strategy and is administered by DSIT. Its remit is manufacturing capex rather than research grants, which matters because Britain's historic problem is not inventing medicines but making them at commercial scale. Accord's Barnstaple facility alone covers 9% of NHS prescriptions by volume; losing it offshore would be a sovereignty problem before it became an employment one. The fund deliberately steers capex away from the research-heavy Oxford-Cambridge-London corridor toward regions with slower wage inflation and available industrial land.

DSIT designed the geographic pattern deliberately. Grant award counts across UK innovation funding are at a 10-year low even as average grant size rises; the policy response has been to consolidate fewer, larger cheques into regional sites that would not otherwise attract private pharmaceutical capex. Devon, Suffolk, Birmingham and South Wales each get a named beneficiary and a dated announcement. Cumulative UK life sciences investment in 2026 stands at £600m; DSIT is targeting £1bn by summer, leaving roughly £400m still to be announced before July with the Golden Triangle deliberately excluded from the remaining pool.

For operators in regional pharma manufacturing, the signal is that LSIMF rounds are now a forecastable policy pipeline rather than a one-off window. For Golden-Triangle biotech, the absence of any London, Oxford or Cambridge cheque this week is itself a commissioning note.

Deep Analysis

In plain English

The government has given over £80m to four pharmaceutical factories in Devon, Birmingham, Suffolk, and South Wales. These are places that usually miss out when big innovation grants are handed out, which tend to cluster around London, Oxford, and Cambridge. Accord Healthcare in Barnstaple makes medicines that cover nearly one in ten NHS prescriptions, meaning millions of people rely on it directly. The grants are designed to modernise the factories and create jobs outside the south-east.

Deep Analysis

Root Causes

NHS procurement of generic medicines is dominated by import from Indian and Eastern European manufacturers; Accord Healthcare's Barnstaple facility covers 9% of NHS prescriptions by volume, but the supply chain remains exposed to logistics disruption because no strategic reserve requirement exists in UK pharmaceutical regulation, unlike the 90-day mandatory reserves France and Germany operate under EU Directive 2001/83/EC.

The UK's post-Brexit exclusion from the EMA's pan-European medicines stockpile system (ECEI) removed a buffer that previously smoothed regional supply shocks; the LSIMF is partly a domestic resilience response to that regulatory gap.

What could happen next?

Consequence
If Codis in Haverhill hires all 29 announced jobs within 12 months and files for a follow-on LSIMF grant in the next funding round, it will become the benchmark case for whether small-site LSIMF investment produces additionality or simply supports existing operators.
Short term · 0.65
Risk
The £400m still to be announced before July 2026 under the £1bn LSIMF target, if concentrated in the three remaining sites, creates a planning and construction queue that will collide with UK construction capacity shortages, likely slipping at least two facilities by 12-18 months.
Medium term · 0.6
Opportunity
Norgine's £20m Hengoed expansion positions South Wales as a candidate for the next round of LSIMF allocations targeting active pharmaceutical ingredient (API) production, which the UK currently imports at 95% dependency on Asian suppliers.
Medium term · 0.5

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The 2015 Life Sciences Industrial Strategy (chaired by Sir John Bell of Oxford) recommended £1bn in biomanufacturing infrastructure outside London and Cambridge; government followed with the BioIndustry Association's Catapult network and the Cell and Gene Therapy Catapult (CGTC) in Stevenage. By 2022, however, the CGTC had drawn most capacity back to the London-Stevenage corridor, replicating the concentration the policy had been designed to break.

Counter-parallel: Ireland's IDA pharma cluster (2000-2015) succeeded in distributing biomanufacturing across Cork, Waterford, and Limerick because the IDA paired manufacturing grants with mandatory clinical trial reciprocity agreements requiring phase II-III trial placement at Irish hospitals; the LSIMF has no equivalent requirement.

Accord Healthcare's £45m grant on a facility producing 9% of NHS prescriptions by volume implies a per-prescription subsidy of roughly £1.80 over a five-year grant amortisation period; replacing equivalent Indian import capacity at current NHS tender prices would cost approximately 40% more per unit.

The Birmingham Precision Health Technologies Accelerator targets cell and gene therapies where UK market size at 2026 prices averages £300,000-£400,000 per patient treatment, making domestic manufacturing economically decisive for NHS affordability.

Consensus view: The Tony Blair Institute for Global Change's 2025 life sciences industrial strategy paper argues that biomanufacturing capacity outside the Oxford-Cambridge-London corridor is the single biggest constraint on scaling UK mRNA and cell-therapy capability; the LSIMF allocation to Barnstaple, Birmingham, Haverhill, and Hengoed directly addresses the bottleneck the Institute identified, but at £80m versus the £500m minimum the report modelled as necessary for internationally competitive scale.

Counter-view: Policy Exchange's 2024 health innovation review contended that regional biomanufacturing grants without co-located clinical trial infrastructure create orphaned capacity: factories that can manufacture but cannot recruit patients for Phase II-III trials within viable travel distances, because research hospitals remain concentrated in the Golden Triangle.

Key tension: Whether the four LSIMF sites can form a functioning dispersed network; sharing logistics, cold-chain, and clinical trial pipelines; or whether each site operates as an isolated facility dependent on London-based procurement relationships.

Sources:DSIT

Mentions:Life Sciences Innovative Manufacturing Fund →DSIT →Accord Healthcare →University of Birmingham Precision Health Technologies Accelerator →Codis →Wales →Suffolk →Cambridge →University of Michigan →Barnstaple →Haverhill →Hengoed →Artemis Accords →

First Reported In

Update #2 · Britain's innovation pipe leaks at both ends

DSIT· 22 Apr 2026

Read original →

Different Perspectives

Beauhurst / UK startup data analysts

Five sub-£50m rounds closed in nine days with zero VCT-backed angel networks on any cap table, confirming the post-cut investor map is forming fast in the £4m–£40m band. The gap is structural: 36.7% of university spinouts raised below £500,000 in 2025, a tier neither the SAIU nor the BBB direct mandate touches.

BVCA / UK VC industry body

The post-VCT investor map has sorted into three non-overlapping pools with no ladder between them; the £500k–£2m band VCTs historically anchored now has no obvious replacement. Beauhurst data showing 36.7% of spinout fundraisings below £500,000 in 2025 suggests the pipeline narrows at the base, compounding within three to five years.

European Commission / EU industrial policy observers

The EC approved €211m of Italian state aid for CamGraPhIC in the same week Britain named five AI hardware startups without specifying a capital instrument. Brussels' willingness to write an industrial-scale factory cheque contrasts with London's pre-announcement of a plan whose mechanism remains unspecified until June.

Sequoia Capital / Lightspeed Venture Partners

Sequoia and Lightspeed co-led Ineffable's $1.1bn seed on research credibility alone, with no product and no revenue; the SAIU minority stake followed their commitment. For US growth funds, the sovereign validator reduces political risk and accelerates LP approval for non-revenue European bets.

HM Treasury / DSIT

DSIT withheld the SAIU cheque size as commercially sensitive, framing the unit's second equity investment as proof sovereign capital can mobilise private-led syndicates. Kendall's RUSI address positioned the SAIU and ARIA as instruments of sovereign control, raising the political commitment attached to the June AI Hardware Plan.

Balderton Capital / Atomico / Index Ventures (UK growth-stage VCs)

At Series B and above, the UK ecosystem is in a strong position: $7.8bn in Q1 is 41% of European VC, seven unicorns were minted in three months, and London remains the deepest late-stage capital market outside the United States.